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Introduction: Although interethnic differences in survival to
cytotoxic chemotherapy in patients with non-small cell lung
cancer exist, an analysis of survival outcomes based on ethnicity
has not yet been fully evaluated systematically using large patient
cohorts. Furthermore, recent trial results may be confounded by
the use of the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI).
Methods: A meta-analysis was performed using trials identified
through MEDLINE. Summary data on median overall survival (OS),
time to progression, progression-free survival, and overall response
rate (ORR) were collected from randomized controlled trials. Out-
comes were compared between Asian and Caucasian studies.
Results: Of the 1182 citations identified, 391 treatment arms (Asian
90 and Caucasian 301) were analyzed. The median OS and ORR in
Asian and Caucasian studies for all chemotherapy regimens was
10.1 and 8.0 months (p  0.001) and 32.2 and 25.9% (p  0.001),
respectively. The median OS in Asian and Caucasian studies for
monotherapy, platinum doublets, and three drugs or more combina-
tion was 9.9 and 6.8 months, 10.4 and 8.6 months, and 9.4 and 8.0
months, respectively (all p 0.001). In studies published pre-EGFR
TKI, the median OS and ORR in Asian and Caucasian studies for all
chemotherapy regimens was 9.1 versus 7.3 months (p  0.001),
respectively, and 29.0 and 23.0% (p  0.006), respectively. The
median OS in Asian and Caucasian studies for monotherapy, plat-
inum doublets, and three drugs or more combination pre-EGFR TKI
was 8.9 and 6.5 months (p  0.005), 9.1 and 7.5 months (p 
0.001), and 9.3 and 7.6 months (p  0.003), respectively. In
third-generation platinum doublets, the median OS in Asian and
Caucasian studies was 11.3 and 9.5 months (p  0.001), respec-
tively, and ORR was 35.0 and 29.8% (p  0.001), respectively.
Conclusion: Ethnic differences in survival and response rate to
chemotherapy exist and should be considered in clinical trial designs
especially in the global context.
Key Words: Non-small cell lung cancer, Meta-analysis, Asian,
Caucasian, Ethnicity, Chemotherapy.
(J Thorac Oncol. 2011;6: 1030–1038)
Lung cancer is a leading cause of cancer deaths worldwidewith the majority of patients presenting with metastatic
non-small cell lung cancer (NSCLC). For patients with ad-
vanced NSCLC with a good performance status (PS), a
platinum-based doublet is currently considered the standard
of care.1 Emerging data suggest ethnic differences in overall
survival (OS) in patients with NSCLC.2 In randomized trials
from Japan, the median OS was 11.4 to 14 months,3,4 whereas
in trials from the United States and Europe of similar che-
motherapy, the median OS was 7.9 and 9.5 months.5,6 As the
epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) gefitinib and erlotinib were introduced in
many Asian countries in 2002 and their use was associated
with an improvement in OS of Asian patients,7–9 survival in
trials from Asia after 2002 may be confounded by EGFR TKI
use. Platinum-based third-generation agents form the back-
bone of first-line NSCLC treatment and are associated with
improved OS compared with second-generation doublets.10
Nevertheless, it is unknown if ethnic differences in survival
exist using third-generation platinum doublets.
Although Asian studies of advanced NSCLC have
reported a longer median OS, an analysis of survival out-
comes based on ethnicity has not yet been evaluated system-
atically in large patient cohorts. As many Asian countries are
in the early period of the tobacco-smoking epidemic, lung
cancer burden is projected to increase in the next two decades
in Asia,11 and with more first-line chemotherapy trials of
advanced stage NSCLC being conducted worldwide, out-
come data from different parts of the world are crucial for the
design of international trials. The study objectives are to
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determine treatment outcomes (median OS, time to progression
[TTP], progression-free survival [PFS], and overall response rate
[ORR]) of patients with advanced stage NSCLC treated with
first-line cytotoxic-based chemotherapy (overall, monotherapy,
platinum doublets, and three drugs or more) in Caucasian and
Asian patients, to determine the same outcomes stratified to
EGFR TKI approval period and to determine these outcomes in
third-generation platinum-based doublets.
METHODS
Search Strategy and Selection Criteria
A systematic literature review on first-line chemotherapy
of patients with advanced stage NSCLC was conducted by a
PUBMED search through the search terms: “nonsmall cell lung
cancer” or “nonsmall-cell lung cancer” limited to “Human,” and
“Clinical Trial, Phase III” or “Randomized Controlled Trial.”
Articles published until September 2010 were considered. No
language restriction was applied. References cited in retrieved
articles were checked for additional relevant articles. Data from
reviews/meta-analyses were not included but articles identified
through references cited were reviewed. Irrelevant and/or dupli-
cate studies were removed after manual curation. Same or
overlapping data from the same authors, trials of chemoradio-
therapy, neoadjuvant and/or adjuvant chemotherapy, and main-
tenance chemotherapy were excluded.
Data Abstraction
The following were retrieved: chemotherapy type (num-
ber and type of agents used), publication year, year of study
initiation and completion, number of patients, gender, country of
patient recruitment, ethnicity, median age, PS, smoking status,
weight loss, stage, histologic subtype, median OS, median TTP,
median PFS, and ORR. Survival data were recorded in months.
Trials from the United States, Australia, and European countries
as well as multinational trials were categorized as Caucasian
ethnicity as the majority of the subjects were Caucasian. Studies
originating from Asian countries were classified as Asian eth-
nicity. Where possible, data were extracted from Asian and
Caucasian subgroups within the United States, European, and
multinational studies for the appropriate treatment arms. Data
were independently abstracted by two reviewers and discrepan-
cies were resolved by consensus and, if necessary, by a third
reviewer. Where data were available, end points were analyzed
for all treatment arms.
For trials with treatment arms involving best supportive
care (BSC), traditional Chinese medications, immunotherapy,
molecular-targeted agents, or chemotherapy combined with
targeted therapy, data were analyzed from the cytotoxic
chemotherapy arms only.
Statistical Analysis
The Mann-Whitney U test was used for comparisons of
continuous variables between Asians and Caucasians. For
comparisons of proportions at baseline, the 2 test was used.
Analysis was performed according to the number of
agents used: monotherapy, platinum doublets and three drugs or
more combinations, pre- and post-EGFR TKI approval, and
third-generation platinum doublets. We defined third-gen-
eration platinum doublets as a platinum (cisplatin or car-
boplatin) combined with a newer agent (gemcitabine, vi-
norelbine, irinotecan, pemetrexed, or the taxanes). For
sensitivity analysis, OS and ORR were reanalyzed after
removal of outliers (defined as 1.5 times interquartile
range), and also by reperforming the comparison between
Asian and Caucasian data after filtering the U.S. and
multinational Caucasian studies.
Median OS was plotted against sample size for all
studies and separately for Asian and Caucasian studies12 in an
attempt to check for publication bias. The Begg and Mazum-
dar’s rank correlation test (Kendall’s tau) was also performed
at a p-value cutoff of 0.1.13 Publication bias was not checked
in the other subgroup analyses as these methods generally do
not work well with small number of studies.14 2 heteroge-
neity tests and I2 statistic for inconsistency were used to
assess statistical heterogeneity across studies within Asian
and Caucasian studies separately.15
Multiple linear regression was performed for median
OS with the following variables: ethnicity, publication year,
platinum agents, use of newer agents, number of cytotoxics,
median age, proportion of patients with poor PS, proportion
of patients with adenocarcinoma, proportion of female pa-
tients, and proportion of stage IV patients.
All statistical tests were two-sided, and PASW Statis-
tics 18 (SPSS Inc, Chicago, IL) was used. A p-value less than
0.05 was considered to indicate statistical significance.
RESULTS
Literature Search
A total of 1182 citations were identified (Figure 1). Ex-
amination of original articles, review articles, and meta-analyses
did not identify any additional randomized clinical trials appro-
priate for inclusion in this analysis. We then reviewed in detail
191 studies (see Table, Supplementary Digital Content 1 for list
of studies analyzed, http://links.lww.com/JTO/A84) and ex-
cluded treatment arms that included BSC, immunotherapy, tra-
ditional Chinese medications, maintenance chemotherapy, and
cytotoxic chemotherapy combined with targeted therapy.
Characteristics of Selected Studies
Overall, 48,369 patients (Asian 6806 and Caucasian
41,563) received 391 treatment arms (Asian 90 and Cauca-
sian 301). Studies from Japan and China comprised 54 and
29% of Asian treatment arms and 12% were subsets of United
States/multinational studies (Figure 1, Table 1, see Table,
Supplementary Digital Content 2 for breakdown of studies by
region, http://links.lww.com/JTO/A85). Significant differ-
ences in the distribution of prognostic factors such as PS,
smoking status, histology, gender, weight loss, and stage
distribution (III versus IV) were seen between Asian and
Caucasian studies (p  0.001), with Asian patients having a
greater proportion of these features (Table 1).
Outcomes between Caucasian and Asian Studies
In a comparison of Asian and Caucasian studies for all
regimens, significant differences in median OS (10.1 and 8.0
months, p  0.001) and ORR (32.2% and 26.0%, p  0.001)
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were seen, whereas the median TTP and median PFS was not
significantly different (Table 2). Although funnel plots showed
no obvious indication of publication bias (result not shown),
Begg’s test showed statistically significant bias in both Asian-
only and Caucasian-only studies, as well as in all studies. There
was significant heterogeneity between all studies (p  0.001,
I2  88%), but once the studies were subgrouped by ethnicity,
there was no evidence of heterogeneity within Asian and Cau-
casian studies (p  1.000, I2  0%).
Outcomes according to the number of agents were
subsequently analyzed. For monotherapy, the median OS in
Asian and Caucasian studies was 9.9 and 6.8 months (p 
0.001), respectively, whereas there was no difference in
ORR. In a comparison of all platinum-based doublets, a
significant difference in median OS (10.4 and 8.6 months,
p 0.001) and ORR (32.4% and 27.5%, p 0.001) was seen
(Figures 2A and 3A). For three-drug or more combination, the
median OS (9.4 and 8.0 months, p 0.001) and ORR (39 and
26%, p  0.004) was significantly higher in Asian than
Caucasian studies (Table 2).
Outcomes between Caucasian and Asian
Studies Published Before and After EGFR TKI
Approval
Pre-EGFR TKI Approval
As EGFR TKI was first approved for use in Asia in
2002,7–9 we divided studies into two eras according to its year
of publication: pre-EGFR TKI (before and including 2001)
and post-EGFR TKI (from 2002 onward). The median OS
and ORR of patients in Asian and Caucasian studies for all
chemotherapy pre-EGFR TKI approval was 9.1 and 7.3
months, respectively (p  0.001) and 29.0 and 23.0%,
respectively (p  0.006). No differences in median TTP or
PFS were seen between Asian and Caucasian studies
(Table 2). In single-agent studies, the median OS was
higher in Asian than Caucasian studies (8.9 and 6.5
months, p  0.005), whereas there was no difference in the
ORR. The median OS of patients in Asian and Caucasian
studies
for all platinum doublets was 9.1 and 7.6 months, respec-
tively (p  0.001) (Figures 2B and 3B) with no difference
in ORR. With three-drug or more combinations, Asian
studies had a higher median OS (9.3 and 7.6 months,
p  0.003) and higher ORR (42.4 and 23.5%, p  0.001;
Table 2).
Post-EGFR TKI Approval
In studies published post-EGFR TKI approval, the
median OS and ORR in Asian and Caucasian studies was
11.0 and 8.9 months (p  0.001) and 32.7 and 29.8% (p 
0.027). In single-agent studies, the median OS was signif-
icantly higher in Asian than Caucasian studies at 11.8
versus 7.1 months (p  0.002), whereas ORR was not
significantly different. The median OS and ORR in plati-
FIGURE 1. Selection of treatment arms.
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TABLE 2. Outcomes between Asian and Caucasian studies according to time period
Median OS Median TTP Median PFS Median ORR
Asian Caucasian p Asian Caucasian p Asian Caucasian p Asian Caucasian p
All time period
Overall 10.1 (87) 8.0 (298) 0.001 4.8 (32) 4.3 (118) 0.061 5.0 (19) 4.8 (62) 0.302 32.2 (81) 26.0 (299) 0.001
Monotherapy 9.9 (9) 6.8 (44) 0.001 3.3 (1) 3.4 (22) 0.942 4.3 (2) 2.6 (6) 0.182 20.5 (9) 16.0 (42) 0.327
Platinum doublets 10.4 (53) 8.6 (129) 0.001 4.7 (24) 4.6 (60) 0.510 5.1 (12) 4.9 (34) 0.468 32.4 (50) 27.5 (132) 0.001
 3 drugs 9.4 (18) 8.0 (94) 0.001 5.1 (6) 4.8 (24) 0.745 5.0 (5) 5.0 (15) 0.595 39.0 (15) 26.0 (94) 0.004
Pre EGFR TKI approval
Overall 9.1 (35) 7.3 (183) 0.001 4.4 (2) 4.0 (57) 0.720 4.7 (2) 4.4 (20) 0.577 29.0 (33) 23.0 (183) 0.006
Monotherapy 8.9 (3) 6.5 (31) 0.005 N/A (0) 3.2 (14) N/A N/A (0) 2.0 (3) N/A 12.0 (3) 15.0 (31) 0.194
Platinum doublets 9.1 (18) 7.5 (65) 0.001 3.5 (1) 4.3 (22) 0.364 N/A (0) 4.3 (9) N/A 28.8 (18) 25.8 (65) 0.184
 3 drugs 9.3 (11) 7.6 (76) 0.003 5.3 (1) 3.9 (18) 0.715 4.7 (2) 5.0 (8) 0.895 42.4 (9) 23.5 (76) 0.001
Post EGFR TKI approval
Overall 11.0 (52) 8.9 (115) 0.001 4.8 (30) 4.6 (61) 0.322 5.0 (17) 4.9 (42) 0.840 32.7 (48) 29.8 (116) 0.027
Monotherapy 11.8 (6) 7.1 (13) 0.002 3.3 (1) 4.0 (8) 0.699 4.3 (2) 2.7 (3) 0.564 22.5 (6) 17.0 (11) 0.108
Platinum doublets 11.0 (35) 9.5 (64) 0.001 4.7 (23) 4.6 (38) 0.465 5.1 (12) 5.0 (25) 0.935 35.0 (32) 29.6 (67) 0.001
 3 drugs 9.5 (7) 8.2 (18) 0.034 5.0 (5) 5.6 (6) 0.289 5.0 (3) 4.8 (7) 0.418 26.0 (6) 37.0 (18) 0.033
3rd Generation Platinum
Doublets
11.3 (33) 9.5 (81) 0.001 4.7 (22) 4.7 (49) 0.597 5.1 (12) 5.0 (28) 0.859 35.0 (30) 29.8 (84) 0.001
OS: overall survival, TTP: time to progression, PFS: progression free survival, ORR: overall response rate, EGFR: epidermal growth factor receptor, TKI: tyrosine kinase
inhibitor, N/A: not applicable, (): number of treatment arms,
TABLE 1. Patient Characteristics of Selected Treatment Arms
Asian, n (%) Caucasian, n (%) Overall, n (%) p
Total No. of randomized patients 6806 (100) 41,563 (100) 48,369 (100)
Median age (yr), median, range 63, 55–76 61, 34–75 61, 38–76 0.003
Performance status
0–1 4489 (66) 28,296 (68) 32,785 (70) 0.001
2 653 (10) 6331 (15) 6984 (15)
Unknown 1664 (24) 6936 (17) 8600 (17)
Smoking status
Never 1025 (15) 374 (1) 1399 (3) 0.001
Former/current 636 (9) 2426 (6) 3062 (7)
Unknown 5145 (76) 38,763 (94) 43,908 (90)
Histological subtype
Adenocarcinoma 3957 (59) 14,653 (35) 18,610 (39) 0.001
Squamous cell carcinoma 1356 (19) 12,436 (30) 13,792 (29)
Others 387 (5) 6593 (16) 6980 (14)
Unknown 1106 (17) 7881 (19) 8987 (18)
Gender
Male 3518 (52) 29,461 (71) 32,979 (68) 0.001
Female 1993 (29) 9965 (24) 11,958 (25)
Unknown 1295 (19) 2137 (5) 3432 (7)
Weight loss
5% 1052 (14) 9991 (24) 11,043 (23) 0.001
5% 277 (4) 5755 (14) 6032 (12)
Unknown 5477 (82) 25,817 (62) 31,294 (65)
Stage
III 1659 (23) 9809 (24) 11,468 (24) 0.001
IV 3555 (54) 23,241 (56) 26,796 (55)
Unknown 1592 (23) 8513 (20) 10,105 (21)
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num doublets Asian and Caucasian studies was 11.0 and
9.5 months (p  0.001) and 35 versus 29.6% (p  0.001),
respectively (Figures 2C and 3C). For studies of three-drug
or more combination, the median OS was higher in Asian
compared with Caucasian studies (9.5 and 8.2 months, p 
0.034), whereas the ORR was lower (26 versus 37%, p 
0.033).
Survival Outcomes between Caucasian and
Asian Studies Containing Third-Generation
Platinum Doublets
No Asian studies were published pre-EGFR TKI era. A
significant difference in median OS (11.3 and 9.5 months, p 
0.001) and ORR (35.0 and 29.8%, p  0.001) was seen in Asian
and Caucasian studies, respectively (Figures 2D and 3D). The
median TTP and PFS in Asian and Caucasian studies was similar
(Table 2).
Regression Analysis
On multiple regression analysis, Asian ethnicity, use of
two or more drugs, lower proportion of patients with poor PS,
and higher proportion of patients with adenocarcinoma were
associated with an improved OS (Table 3).
It is unknown if the higher OS in Asians is related to
better response to treatment or better overall prognosis. An
analysis of BSC data would be useful, thus we reviewed the
results of our literature search. Only one study from Asia was
identified,16 and no difference in OS was seen between this
study and the Caucasian studies of BSC (data not shown).
FIGURE 2. Median survival in Asian and Caucasian studies containing (A) all platinum-based doublets, (B) all platinum-based
doublets pre-EGFR TKI era, (C) all platinum-based doublets post-EGFR TKI era, and (D) platinum-based third-generation dou-
blets. Bubble size corresponds to the study sample size.
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DISCUSSION
In our analysis, we found a significant difference in the
median OS of patients from Asian compared with Caucasian
studies regardless of the number of chemotherapy drugs
administered. To account for EGFR TKI as a confounding
factor, studies published before and after the introduction of
EGFR TKI were analyzed. The median OS in Asian studies
was higher than Caucasian studies published before EGFR
TKI approval regardless of number of agents used. As third-
generation agents in combination with platinum are associ-
ated with improved survival compared with second-genera-
tion regimens and constitute the backbone of current first-line
cytotoxic therapy, we compared outcomes in studies using
third-generation platinum doublets. A higher median OS and
ORR was seen in Asian studies compared with Caucasian
studies treated with third-generation platinum doublets.
Our meta-analysis strengthens reports Asian patients have
a better survival than Caucasian patients with NSCLC receiving
chemotherapy. Using a common study protocol where patients
from Japan and the United States were treated with carboplatin
and paclitaxel, the median OS was 12 to 14 months and 9
months, respectively (p  0.0006).17 Registry-based studies
have reported differences in survival between Caucasians and
Asians. In a study using a regional California Cancer Registry
(CCR), Asian ethnicity was an independent favorable prognostic
factor for survival independent of smoking status.18 In a com-
parison of cancer registries from Japanese hospitals and the
identical CCR, Japanese ethnicity was an independent factor for
survival versus Caucasian.19 In a similar study from a Korean
cancer institute comparing with the same CCR, Korean ethnicity
was an independent prognostic factor.20 Where the previous
studies used registry data that encompassed patients of all stages
FIGURE 3. Overall response rates in Asian and Caucasian studies containing (A) all platinum-based doublets, (B) all platinum-
based doublets pre-EGFR TKI era, (C) all platinum-based doublets post-EGFR TKI era, and (D) platinum-based third-generation
doublets. Bubble size corresponds to the study sample size.
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and all treatment types, our findings are applicable to patients
with advanced NSCLC treated with chemotherapy.
A significant difference in ORR was seen between
Asian and Caucasian studies regardless of the number of
cytotoxic agents used. We have previously reported a higher
ORR in Asian compared with Caucasian patients with
NSCLC treated with carboplatin/docetaxel (65 versus 31%,
p  0.01).21 Logistic regression analysis showed ethnicity
was the only significant independent predictor for response to
treatment. In contrast, in a report where patients from the
United States and Japan used a standardized trial protocol and
received carboplatin/paclitaxel, similar ORR was seen in the
United States (33%) and Japanese trials (32 and 37%).17 The
difference in ORR seen in our analysis may reflect variation in
methodology and response assessment between studies rather
than actual ethnic differences. Despite the higher ORR, no
difference in TTP or PFS between Asian and Caucasian studies
was seen.
The strengths of this report were it analyzed random-
ized trial data and several outcomes (median OS, TTP, PFS,
and ORR) were measured. Data obtained from randomized
clinical trials are advantageous as it provides more accurate
and reliable assessment of data. Hence, the collection of data
related to patient characteristics, histology, stage, and treat-
ment would be standardized within a trial. Despite differ-
ences in study methodology, the prospective evaluation of
treatment response and survival follow-up would enable a
more reliable assessment of ORR, TTP, PFS, and OS.
We reported a higher proportion of adenocarcinoma, fe-
male gender, PS, smoking status, and stage III in Asian studies.
The imbalance in these recognized prognostic factors may ac-
count for the difference in OS between Asians and Caucasians
studies.22–25 Other factors such as gene expression, genetic
polymorphisms, and activating EGFR mutation status may also
play a role. In a recent study reported in abstract form, putative
chemotherapy biomarkers of chemosensitivity (excision-repair
cross-complementing [ERCC], ribonucleotide reductase M1
[RRM1], and thymidylate synthetase [TYMS]) were more likely
in adenocarcinoma.26 Polymorphisms in genes involved in do-
cetaxel and platinum metabolic pathway such as cytochrome
P450 3A4 [CYP3A4], ATP-binding cassette, sub- family B,
member 1 [ABCB1] and ERCC2 may account for variation in
drug efficacy.27–29 Activating EGFR mutations is also a prog-
nostic factor,8,30,31 and given the higher frequency of activating
EGFR mutations in Asians,32 the difference in OS in studies
published pre-EGFR TKI approval may be because of the
difference in frequency in these mutations. The difference in OS
in Asian compared with Caucasian studies after 2002 is likely
because of the use of EGFR TKI.
Other influences on OS include differences in culture
and attitude to the management of advanced malignancies,
lifestyle, and socioeconomic status. Differences in medical
care such as level of complexity and accessibility to health
care facilities exist and may influence outcomes.33 Previ-
ous studies have reported that the availability and access to
health care can influence lung cancer outcomes34 and that
outcomes were similar if there was unlimited access to
care.35
It is important to note that this study encountered
difficulties common to most meta-analyses. First, it was
based on summary data rather than individual patient data.
Hence, multivariate analysis for confounding factors such as
histological subtypes, gender, weight loss, and smoking sta-
tus was not conducted. Multiple linear regression analysis,
however, was performed to delineate the major determinants
of survival, and confirmed ethnicity was indeed an indepen-
dent and major factor for median OS.
Our search was limited to published studies and not
unpublished trials or results in abstract form, thus publi-
cation bias may be a factor. We attempted to mitigate this
by not applying any language restriction, which is espe-
cially important as a significant proportion of trials con-
ducted on Asian patients were published in Chinese and
Japanese journals. To check for publication bias, the study
sample size was plotted against the median OS instead of
the recommended method of plotting standard error or
variance against the main effect of interest. This approach
was conducted as confidence intervals were provided for
median OS in only 108 of 391 study treatment arms, (28%)
and different methods were used in the calculation of the
confidence intervals, thus rendering it impossible to obtain
the corresponding standard error. Although this was pre-
viously reported to be generally less ideal,36 in some
situations, sample size might be more strongly related to
the probability of publication than the level of statistical
significance.36 Furthermore, funnel plots did not show any
evidence of publication bias.
Another limitation of this study was that the analysis
was conducted on trials published over a period of 35 years
TABLE 3. Multiple Linear Regression Analysis of Median
Survival
Factor
Regression
Coefficient
Standard
Error p
Ethnicity 2.181 0.371 0.001
Year of publicationa Excluded 0.052
Use of platinum agents Excluded 0.298
Use of newer agentsb Excluded 0.059
No. of agentsc 0.952 0.368 0.011
Median age Excluded 0.197
Proportion of patients with
poor performance statusd
0.024 0.008 0.003
Proportion of patients with
adenocarcinoma subtype
0.026 0.012 0.027
Proportion of female patients Excluded 0.380
Proportion of stage IV patients Excluded 0.817
a Before versus after epidermal growth factor receptor tyrosine kinase inhibitor
approval.
b Newer agents defined as paclitaxel, docetaxel, gemcitabine, vinorelbine, pem-
etrexed, and irinotecan; whereas older agents were defined as agents other than newer
agents (including vinca alkaloids, etoposide, mitomycin, or ifosfamide).
c Monotherapy versus 2 drugs.
d Defined as PS 2.
PS, performance status.
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(1975–2010). We performed subgroup analysis on: pre- and
post-EGFR TKI era and era of third-generation platinum
doublets to limit the differences in treatment efficacy over
time. In addition, on linear regression analysis, publication
year was not associated with survival.
The generalization of results to represent Asian and
Caucasian data is imperfect. We attempted to check on the
robustness of our definition by repeating the analyses after
removal of U.S. and multinational trials. There was no dif-
ference in the results observed thus providing further support
that our observations are indeed true. The uneven number of
studies from Asian countries, with data derived mainly from
China, Korea, Japan, and Taiwan, could also provide a source
of bias. As such, our analysis may reflect outcome from East
Asia rather than Asia in general.
In conclusion, we found significant differences in OS
and ORR according to ethnicity of patients treated with
cytotoxic chemotherapy. Furthermore, we have provided a
systematic analysis of treatment outcomes according to the
number of cytotoxic agents and time period relative to EGFR
TKI approval. Ethnic differences in response and survival to
chemotherapy should be recognized and are important in
clinical trial design especially in the global context.
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